Evidence map›Paper›PMID 32550528›Full record

ArticleContraception: X2019

Trends in subcutaneous depot medroxyprogesterone acetate (DMPA-SC) use in Burkina Faso, the Democratic Republic of Congo and Uganda.

Philip Anglewicz, Pierre Akilimali, Georges Guiella, Patrick Kayembe, Simon P S Kibira, Fredrick Makumbi, Amy Tsui, Scott Radloff

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contraception: X, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Philip AnglewiczJohns Hopkins Bloomberg School of Public Health, Department of Population, Family and Reproductive Health, 615 N. Wolfe Street E4533, Baltimore, MD 21205, USA.
Pierre AkilimaliSchool of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Georges GuiellaInstitut Supérieur des Sciences de la Population, University of Ouagadougou, Ouagadougou, Burkina Faso.
Patrick KayembeSchool of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Simon P S KibiraDepartment of Community Health and Behavioral Sciences, Makerere University School of Public Health, Kampala, Uganda.
Fredrick MakumbiDepartment of Epidemiology and Biostatistics, Makerere University School of Public Health, Kampala, Uganda.
Amy TsuiJohns Hopkins Bloomberg School of Public Health, Department of Population, Family and Reproductive Health, 615 N. Wolfe Street E4533, Baltimore, MD 21205, USA.
Scott RadloffJohns Hopkins Bloomberg School of Public Health, Department of Population, Family and Reproductive Health, 615 N. Wolfe Street E4533, Baltimore, MD 21205, USA.
Johns Hopkins University · USMakerere University · UGUniversity of Kinshasa · CDUniversité Joseph Ki-Zerbo · BF

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesSubcutaneous depot medroxyprogesterone acetate (DMPA-SC) is seen as a valuable innovation in family planning, but little is known about trends in DMPA-SC use or characteristics of users. Using data from Burkina Faso, the Democratic Republic of Congo (DRC) and Uganda, we measured trends in DMPA-SC and identified characteristics associated with DMPA-SC use. STUDY

designWe used repeated cross-sectional representative data collected between 2016 and 2019. First, we plotted trends in DMPA-SC use for all women and married women. Next, we presented the sociodemographic and family-planning-related characteristics of DMPA-SC users. Finally, we conducted weighted multivariate logistic regression analysis to examine how DMPA-SC users were different from women (1) using all other modern methods combined and (2) not using any modern method.

resultsDMPA-SC use increased monotonically in all three countries. Many DMPA-SC users were first-time users of modern contraception (54.5% in Burkina Faso, 34.6% in DRC, 50.7% in Uganda). Never-married women had lower odds than married women of using DMPA-SC (compared to other modern methods) in all three countries [Burkina Faso adjusted odds ratio (AOR) 0.40, 95% confidence interval (95% CI) 0.20-0.80; DRC AOR 0.31 95% CI 0.10-0.93; Uganda AOR 0.24; 95% CI 0.08-0.71]. Level of education was positively associated with DMPA-SC use (compared to no use) (Burkina Faso AOR 1.79; 95% CI 1.03-3.14; Uganda AOR 3.23; 95% CI 1.33-7.84).

conclusionsDMPA-SC is a rapidly growing method in these settings. Despite the comparable levels of and increases in use for all three countries, the characteristics associated with DMPA-SC use generally differed across countries. IMPLICATIONS: This is the first analysis of patterns of DMPA-SC use with representative data for African countries. Our results confirm that DMPA-SC is increasingly popular, although the profile of users varies across settings.

Indexed as

Burkina FasoContraceptive useDemocratic Republic of CongoDMPA-SCFamily planningSayana® PressUganda

Identifiers

PMID32550528
PMCPMC7286145
OpenAlexW2983754147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.